Onglyza (Saxagliptin) is a prescription oral medication designed to help manage type 2 diabetes in adults. It belongs to a class of medicines known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones in the body. These hormones play an important role in regulating blood sugar by stimulating the release of insulin after meals and decreasing the amount of sugar produced by the liver. As a result, Onglyza helps lower blood glucose levels and maintain long-term control over diabetes.
For many patients in the United States, the United Kingdom, and Canada, Onglyza is a convenient and effective choice for diabetes management. It can be used as a standalone treatment or in combination with other diabetes medications such as metformin or insulin to achieve better glucose control. Regular use of Onglyza not only improves daily blood sugar readings but also helps reduce the risk of diabetes-related complications, including kidney problems, nerve damage, heart disease, and vision issues.
Onglyza is taken orally, usually once a day, with or without food, making it easy to fit into a daily routine. Patients should continue following a balanced diet, exercise plan, and regular monitoring of blood sugar levels while taking this medicine for the best results.
Common side effects may include headache, upper respiratory tract infections, and stomach upset. While generally well tolerated, some individuals may experience more serious side effects such as low blood sugar (when combined with other medications), allergic reactions, or pancreatitis. It is important to consult a healthcare professional before starting Onglyza, especially if you have a history of kidney disease, heart failure, or pancreatitis.
By choosing Onglyza (Saxagliptin), patients gain access to a reliable, clinically proven treatment that supports healthier blood sugar levels and promotes long-term well-being.